Avaleht › Endomeetriumivähk › Massachusetts
Endomeetriumivähk kliinilised uuringud osariigis Massachusetts
53 uuringut haiguse Endomeetriumivähk jaoks otsivad osalejaid osariigis Massachusetts.
Linnad osariigis Massachusetts
Ametlik uuringutekst (inglise keeles)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- ja veel 1
VärbamineFaas 2
Kõik vanused · Kõik sood · Uuendatud 2. okt 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Värbamine
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT07059884Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 2. okt 2026 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2026 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 19 ja vanemad · Kõik sood · Uuendatud 1. okt 2026 · NCT06586957Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. sept 2026 · NCT06218914Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Naised · Uuendatud 25. sept 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Naised · Uuendatud 24. sept 2026 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Massachusetts General Hospital Cancer Center, Boston
- Baystate Medical Center, Springfield
- UMass Memorial Medical Centre, Worcester
VärbamineFaas 2
Vanused 18 ja vanemad · Naised · Uuendatud 24. sept 2026 · NCT05640999Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07114601Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 21. sept 2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Tufts Medical Center ( Site 6052), Boston
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 17. sept 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. sept 2026 · NCT07109726ALPINE: Maintenance Letrozole/Abemaciclib
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- ja veel 1
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT06366347A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 11. sept 2026 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 10. sept 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- UMass Memorial Medical Ctr, Worcester
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 9. sept 2026 · NCT07166094Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Naised · Uuendatud 3. sept 2026 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Boston
VärbamineFaas 3
Vanused 18 ja vanemad · Naised · Uuendatud 3. sept 2026 · NCT06989112Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Värbamine
Vanused 18 ja vanemad · Naised · Uuendatud 31. aug 2026 · NCT04839614A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 27. aug 2026 · NCT07227168A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 26. aug 2026 · NCT07383506Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1/2
12 Months – 30 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 21. aug 2026 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
VärbamineFaas 1/2
Vanused 18–130 · Kõik sood · Uuendatud 21. aug 2026 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Dana Farber Cancer Institute, Boston
VärbamineFaas 2
Vanused 18 ja vanemad · Naised · Uuendatud 21. aug 2026 · NCT05548296A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 19. aug 2026 · NCT04104776A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. aug 2026 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 17. aug 2026 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 12. aug 2026 · NCT06840886A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 11. aug 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 4. aug 2026 · NCT05579366First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 7. juuli 2026 · NCT05768139A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. juuni 2026 · NCT07458347Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 19–110 · Kõik sood · Uuendatud 29. juuni 2026 · NCT02012699A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. juuni 2026 · NCT05377996Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. juuni 2026 · NCT06993844Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.